The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hyperprogressive disease in advanced triple-negative breast cancer (aTNBC) treated with immunotherapy (IO).
 
Tira Jing Ying Tan
Consulting or Advisory Role - Novartis; Pfizer
Research Funding - Bayer; Novartis
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Merck Sharp & Dohme; Pfizer
 
David W. Cescon
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Genomic Health; GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - GlaxoSmithKline (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Lisa Wang
No Relationships to Disclose
 
Eitan Amir
Honoraria - Agendia; Apobiologix; Myriad Genetics
Expert Testimony - Genentech/Roche
 
Daniella Vieira
No Relationships to Disclose
 
Kaitlyn Zammit
No Relationships to Disclose
 
David Warr
Consulting or Advisory Role - Helsinn Healthcare; Merck
Speakers' Bureau - Merck
Research Funding - Merck
 
Christine Elser
No Relationships to Disclose
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunovaccine; Merck; Novartis
Research Funding - Merck; Takara Bio
Expert Testimony - Merck
 
Albiruni Ryan Abdul Razak
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Merck
Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CASI Pharmaceuticals; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics; Lilly; MedImmune; Merck; Novartis; Pfizer; Roche/Genentech
 
Aaron Richard Hansen
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Anna Spreafico
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Oncorus
Research Funding - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck; Northern Biologics; Novartis; Surface Oncology; Surface Oncology; Symphogen
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Merck
 
Lillian L. Siu
Leadership - Agios (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - AstraZeneca/MedImmune; Loxo; Merck; MorphoSys; Roche; Symphony Evolution
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Symphony Evolution (Inst)
 
Philippe L. Bedard
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Nektar (Inst); Novartis (Inst); PTC Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); SERVIER (Inst); SignalChem (Inst)